A new perspective on the pharmacoeconomics of colchicine

Current Medical Research and Opinion

Volumn 27, Issue 5, 2011, Pages 931-937

  Wertheimer, Albert I ^a   Davis, Matthew W ^b   Lauterio, Thomas J ^b  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b URL Pharma Inc   (United States)

Author keywords

Colchicine; Cost benefit; Gout; Gout flare; Managed care; Pharmacoeconomics

Indexed keywords

COLCHICINE; COLCRYS; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG CONTRAINDICATION; DRUG COST; GASTROINTESTINAL SYMPTOM; GOUT; HEALTH CARE COST; HUMAN; MONEY; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CHRONIC DISEASE; COLCHICINE; COSTS AND COST ANALYSIS; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; UNITED STATES; URIC ACID;

EID: 79954503178     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.563284     Document Type: Review

References (25)

1. Briesacher BA, Andrade SE, Fouayzi H, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437-44.
2. Becker, M, Schumacher, HR, Esponoza LR, et al. The urate-lowering and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRM trial. Arthritis Res Ther 2010;12:R63.
3. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62:1060-8.
4. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med 1987; 17:301-4. (Pubitemid 18014682)
5. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32. (Pubitemid 39610535)
6. Paulus HE, Schlosstein LH, Godfrey RG, et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974;17:609-14.
7. Becker MA, Shumacher Jr HR, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. Arthritis Rheum 2005;52:916-23.
8. Becker MA, Shumacher Jr HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61. (Pubitemid 41781828)
9. Terkeltaub RA, Furst D, DiGiacinto JL. Pharmacokinetic studies of differential inhibitors of cytochrome P450 3A4 and P-glycoprotein provide novel, specific dosing recommendations for colchicine to avoid drug-drug interactions. Arthritis Rheum, Submitted for publication.
10. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of nonsteroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342:c7086.
11. Fosbol EL, Kober L, Torp-Pederson C, et al. Cardiovascular safety of nonsteroidal anti-inflammatory drugs among healthy individuals. Expert Opin Drug Saf 2010;9:1-11.
12. Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in health subjects. Ann Intern Med 1982;96:317-20. (Pubitemid 12187508)
13. Marketed Unapproved Drugs-Compliance Policy Guide (CPG). Guidance for FDA Staff and Industry. Food and Drug Administration, Center for Drug Evaluation and Research Website. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070290.pdf. Published June 2006.
14. Kim SY, Choi HK. Gout and quality of life. J Rheumatol 2009;36:865-8.
15. Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009;36:1041-8.
16. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of Life? A case-control study. Rheumatology 2007;46:1441-4. (Pubitemid 47317091)
17. Kleinman NL, Brook RA, Patel PA, et al. The impact of gout on work absence and productivity. Value Health 2007;10:231-37. (Pubitemid 47077244)
18. Kim KY, Schumacher HR, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593-617. (Pubitemid 36805619)
19. Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin 2006;22:1381-9. (Pubitemid 44085590)
20. Halpern R, Fuldeore MJ, Mody RR, et al. The effect of serum urate on gout flares and their associated costs. J Clin Rheumatol 2009;15:3-7.
21. Wu EQ, Patel PA, Mody RR, et al. Frequency, risk and cost of gout-related episodes among elderly: does serum uric acid level matter? J Rheumatol 2009;36:1032-40.
22. Wu EQ, Patel PA, Yu AP, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm 2008;14:164-75. (Pubitemid 351453817)
23. www.drugstore.com accessed June 12, 2010.
24. Gislason GH, Rasmussen JN, Abdilstrom SZ. Increased mortality and cardiovascular morbidity associated with the use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009;169:141-9.
25. Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. Am J Manag Care 2005;11(15 Suppl):S459-64 (Pubitemid 41720938)